Alectinib
- Generic Name
- Alectinib
- Brand Names
- Alecensa, Alecensaro
- Drug Type
- Small Molecule
- Chemical Formula
- C30H34N4O2
- CAS Number
- 1256580-46-7
- Unique Ingredient Identifier
- LIJ4CT1Z3Y
- Background
Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC cells. Inhibition of ...
- Indication
Alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this ...
- Associated Conditions
- Refractory, metastatic Non small cell lung cancer
- Associated Therapies
- -
Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy
- Conditions
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT02271139
- Locations
- 🇺🇸
LAC USC Medical Center, Los Angeles, California, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸Allegheny Cancer Center, Pittsburgh, Pennsylvania, United States
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 673
- Registration Number
- NCT02091141
- Locations
- 🇺🇸
University Of Chicago Medical Center; Section Of Hematology/Oncology, Chicago, Illinois, United States
🇺🇸MD Anderson, Houston, Texas, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
- Conditions
- Interventions
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 303
- Registration Number
- NCT02075840
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇨🇦Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada
🇺🇸Beth Israel Deaconess Med Ctr; Hem/Onc, Boston, Massachusetts, United States
A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.
- Conditions
- Interventions
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 42
- Registration Number
- NCT02023125
A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT02013219
- Locations
- 🇺🇸
Yale University School Of Medicine, New Haven, Connecticut, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇭🇰The Chinese University of Hong Kong, Shatin, Hong Kong
A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2016-10-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT01984229
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 134
- Registration Number
- NCT01871805
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, Commack, New York, United States
🇺🇸UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸UCLA, Los Angeles, California, United States
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
- First Posted Date
- 2013-02-28
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 138
- Registration Number
- NCT01801111
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸UCLA Cancer Center; Premiere Oncology, A Medical Corporation, Santa Monica, California, United States
🇺🇸Washington University; Wash Uni. Sch. Of Med, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.